{
    "clinical_study": {
        "@rank": "4773", 
        "arm_group": [
            {
                "arm_group_label": "QAW039", 
                "arm_group_type": "Experimental", 
                "description": "Eligible patients will receive QAW039 per os 450 mg daily dose."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo capsules"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether QAW039 is safe and has beneficial effects\n      in people who have moderate to severe atopic dermatitis (AD)."
        }, 
        "brief_title": "Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Atopic Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Presence of atopic dermatitis confirmed by Itchy skin condition in the past 12 months\n             plus three, or more, of the following:\n\n               -  History of involvement of the skin creases (fronts of elbows, behind knees,\n                  fronts of ankles, around neck or around eyes)\n\n               -  Personal history of asthma or hay fever\n\n               -  History of generally dry skin in the past year\n\n               -  Onset before age of 2 years\n\n               -  Visible flexural dermatitis\n\n          -  Patients with an EASI score of \u226515 at screening and stable AD (not currently\n             experiencing an acute flare of their AD).\n\n          -  Patients that have been treated with topical corticosteroids or topical calcineurin\n             inhibitors on at least one occasion, or could not use topical drugs (due to\n             contraindications, side effects, etc.) and are candidates for or have previously\n             received systemic treatment.\n\n        Key Exclusion Criteria:\n\n          -  Pregnant or nursing (lactating) women\n\n          -  Women of child-bearing potential unless they are using a effective method of birth\n             control (as further defined in study protocol)\n\n          -  Recent previous systemic treatment with phototherapy, systemic antihistamines,\n             immunosuppressive agents such as cyclosporine, mycophenolate, or oral tacrolimus, or\n             therapeutic proteins."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "92", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01785602", 
            "org_study_id": "CQAW039X2201", 
            "secondary_id": "2012-005321-78"
        }, 
        "intervention": [
            {
                "arm_group_label": "QAW039", 
                "description": "Capsules", 
                "intervention_name": "QAW039", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Capsules", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Atopic eczema", 
            "Skin Diseases"
        ], 
        "lastchanged_date": "January 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phillip", 
                        "country": "Australia", 
                        "state": "Australian Capital Territory", 
                        "zip": "2606"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Benowa", 
                        "country": "Australia", 
                        "state": "Queensland", 
                        "zip": "4217"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Woolloongabba", 
                        "country": "Australia", 
                        "state": "Queensland", 
                        "zip": "4102"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vienna", 
                        "country": "Austria"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bruxelles", 
                        "country": "Belgium", 
                        "zip": "1200"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "3000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Li\u00e8ge", 
                        "country": "Belgium", 
                        "zip": "4000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sofia", 
                        "country": "Bulgaria", 
                        "zip": "1612"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "10117"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bonn", 
                        "country": "Germany", 
                        "zip": "53105"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany", 
                        "zip": "01307"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Muenster", 
                        "country": "Germany", 
                        "zip": "48149"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1105 AZ"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Groningen", 
                        "country": "Netherlands"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands", 
                        "zip": "3508 GA"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bucharest", 
                        "country": "Romania", 
                        "zip": "050159"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bucharest", 
                        "country": "Romania", 
                        "zip": "011461"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cape Town", 
                        "country": "South Africa", 
                        "state": "Western Province", 
                        "zip": "7700"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durban", 
                        "country": "South Africa", 
                        "zip": "4001"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "Austria", 
                "Belgium", 
                "Bulgaria", 
                "Germany", 
                "Netherlands", 
                "Romania", 
                "South Africa"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled, Parallel Group Study Evaluating Efficacy and Safety of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Austria: Bundesministerium f\u00fcr Gesundheit", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Eczema Area and Severity Index (EASI) score in comparison to placebo.", 
                "measure": "Change from baseline in Eczema Area and Severity Index", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 12 weeks"
            }, 
            {
                "description": "Number of participants with adverse events as measured by vital signs, ECG, laboratory tests and collection of adverse events.", 
                "measure": "Number of Participants with Adverse Events used to assess Safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01785602"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "EASI score in comparison to placebo.", 
            "measure": "Change from baseline in Eczema Area and Severity Index", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 4 weeks, and 8 weeks"
        }, 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}